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Prognosis of Differentiated Thyroid Cancer
in Relation to Serum Thyrotropin and
Thyroglobulin Antibody Status at Time of Diagnosis
Donald S.A. McLeod,1–3 David S. Cooper,4 Paul W. Ladenson,4 Kenneth B. Ain,5 James D. Brierley,6
Henry G. Fein,7 Bryan R. Haugen,8 Jacqueline Jonklaas,9 James Magner,10 Douglas S. Ross,11
Monica C. Skarulis,12 David L. Steward,13 Harry R. Maxon,14 and Steven I. Sherman15
for the National Thyroid Cancer Treatment Cooperative Study Group
Background: Serum thyrotropin (TSH) concentration and thyroid autoimmunity may be of prognostic impor-
tance in differentiated thyroid cancer (DTC). Preoperative serum TSH level has been associated with higher DTC
stage in cross-sectional studies; data are contradictory on the significance of thyroid autoimmunity at the time of
diagnosis.
Objective: We sought to assess whether preoperative serum TSH and perioperative antithyroglobulin antibodies
(TgAb) were associated with thyroid cancer stage and outcome in DTC patients followed by the National
Thyroid Cancer Treatment Cooperative Study, a large multicenter thyroid cancer registry.
Methods: Patients registered after 1996 with available preoperative serum TSH (n = 617; the TSH cohort) or
perioperative TgAb status (n = 1770; the TgAb cohort) were analyzed for tumor stage, persistent disease, re-
currence, and overall survival (OS; median follow-up, 5.5 years). Parametric tests assessed log-transformed TSH,
and categorical variables were tested with chi square. Disease-free survival (DFS) and OS was assessed with Cox
models.
Results: Geometric mean serum TSH levels were higher in patients with higher-stage disease (Stage III/IV = 1.48
vs. 1.02 mU/L for Stages I/II; p = 0.006). The relationship persisted in those aged ‡45 years after adjusting for sex
( p = 0.01). Gross extrathyroidal extension ( p = 0.03) and presence of cervical lymph node metastases ( p = 0.003)
were also significantly associated with higher serum TSH. Disease recurrence and all-cause mortality occurred in
37 and 38 TSH cohort patients respectively, which limited the power for survival analysis. Positive TgAb was
associated with lower stage on univariate analysis (positive TgAb in 23.4% vs. 17.8% of Stage I/II vs. III/IV
patients, respectively; p = 0.01), although the relationship lost significance when adjusting for age and sex
( p = 0.34). Perioperative TgAb was not an independent predictor of DFS (hazard ratio = 1.12 [95% confidence
interval = 0.74–1.69]) or OS (hazard ratio = 0.98 [95% confidence interval = 0.56–1.72]).
Conclusions: Preoperative serum TSH level is associated with higher DTC stage, gross extrathyroidal extension,
and neck node metastases. Perioperative TgAb is not an independent predictor of DTC prognosis. A larger
cohort is required to assess whether preoperative serum TSH level predicts recurrence or mortality.
This work was presented in part at the 82nd Annual Meeting of the American Thyroid Association, Quebec City, Canada, September 2012.
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Although most patients diagnosed with differentiatedthyroid cancer (DTC) have a good prognosis, a signifi-
cant proportion of patients have persistent or recurrent dis-
ease, and a minority will die from thyroid cancer. Accurate
risk stratification is needed to determine which patients will
benefit from aggressive therapy and monitoring, but current
systems fail to account for a significant proportion of patients’
adverse disease outcomes (1,2). Therefore, novel baseline
prognostic factors that could be added to risk stratification
algorithms are required.
Two potential prognostic factors are serum thyrotropin
(TSH) and thyroid autoimmunity. TSH is the major growth
factor and regulator of the thyroid. Serum TSH concentration
is directly associated with the risk of cancer in a thyroid
nodule (3,4), and TSH suppression improves prognosis of
high-risk DTC patients (5–7). However, it is less clear whether
TSH is associated with stage of disease and other prognostic
surrogates (3). Antithyroglobulin antibody (TgAb) and anti-
thyroid peroxidase antibody (TPOAb) are serologic markers
of autoimmune thyroid disease. Elevated TgAb is present in
approximately 25% of thyroid cancer patients, and persistent
or reemerging TgAb can signal recurrent disease (8). Whether
thyroid autoimmunity also plays a role in DTC pathogenesis
or whether autoimmunity is actually protective (9,10) remains
uncertain.
In order to assess the prognostic significance of laboratory
measures of serum TSH concentration and TgAb status at the
time of patients’ thyroid cancer diagnosis, we analyzed pro-
spective data from The National Thyroid Cancer Treatment
Cooperative Study (NTCTCS), a large nonrandomized thy-
roid cancer registry.
Methods
Registry protocol and data collection
The data collection and analytical methods of the NTCTCS
have been described elsewhere (6,11–16). Briefly, 11 North
American centers are current members, with registration be-
ginning in January 1987 and continuing through to 2011. New
patients were registered within 3 months of their initial sur-
gery. Institutional review boards (IRB) of contributing centers
approved the study, and ongoing oversight of the project
occurs through the University of Texas M.D. Anderson Can-
cer Center Institutional Review Board, where the central da-
tabase is currently maintained. As of the beginning of 2011,
4808 patients have been included in the database, represent-
ing 31,876 person-years of follow-up.
Management of patients was nonrandomized and solely at
the discretion of their treating physicians on the basis of
perceived best practice and clinical need, independent of
registry participation. Prespecified baseline demographic,
clinical, histologic, and radiologic data were entered into a
PC-based clinical data management system locally (Medlog,
v2000-2, Incline Village, NV) and transmitted to the central
registry database. Clinical status, investigations, and treat-
ments were updated on a yearly basis.
Presurgical serum TSH was measured using a second- or
third-generation assay and the result recorded in mU/L.
TgAb were classified as either positive or negative, based on
institutional reference ranges. Histologic subtype was ab-
stracted from pathology reports. Co-existing benign thyroid
diagnoses, preoperative levothyroxine use, preoperative
thyroid scans, TPOAb status, and TSH receptor antibody
status were not recorded. Disease stage was classified using a
unique registry staging system (Table 1) (12). Conversion to
the latest American Joint Committee on Cancer (7th edition)
stage (17) is not possible because tumor size was recorded
categorically and central versus lateral cervical node metas-
tases were not differentiated in data collection. All thyroid
cancer-related treatment was recorded. Individual investiga-
tors assessed and recorded the presence of baseline residual
disease and recurrence. Where possible, the causes of death
were reviewed and mortality data confirmed through the
Social Security Death Index.
Eligibility criteria
We assessed patients with DTC (papillary, follicular, or
Hürthle cell carcinomas) who had available presurgical serum
TSH and/or perioperative TgAb (TgAb available within 3
Table 1. NTCTCS Staging Classification
Papillary carcinoma Follicular carcinoma
Age <45 Age ‡45 Age <45 Age ‡45
Primary tumor size
< 1 cm I I I II
1–4 cm I II I III
> 4 cm II III II III
Primary tumor description
Microscopic multifocal I II I III
Macroscopic multifocal or
macroscopic tumor capsule invasion
I II II III
Microscopic extraglandular invasion I II I III
Macroscopic extraglandular invasion II III II III
Poor differentiation n/a n/a III III
Metastases
Cervical lymph node metastases I III I III
Extracervical metastases III IV III IV
The final staging classification is the highest of the individual Primary tumor size, Primary tumor description, and Metastases scores.
NTCTCS, The National Thyroid Cancer Treatment Cooperative Study.
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months of diagnosis). These data were not available for pa-
tients enrolled prior to 1996.
Statistical analysis
For the cross-sectional analysis, thyroid cancer stage (high-
risk = Stages III/IV vs. low-risk = Stages I/II) was analyzed
with respect to serum TSH and TgAb status. Serum TSH was
assessed as both a continuous (assessing geometric mean,
tested with t-tests for crude analyses and via regression
models stratified by age and adjusted by sex) and a categorical
variable (tested with Cochrane–Armitage test for trend). Cut
points for the four TSH categories were determined as fol-
lows: cut points for low serum TSH and high serum TSH were
prespecified at 0.4 mU/L and 4.5 mU/L respectively; patients
with serum TSH within this range were divided at the median
serum TSH, which was 1.5 mU/L. Analyses were also per-
formed comparing TSH levels in relation to tumor size, in-
vasion, and metastases (both nodal and distant). We used
logistic regression to assess the association between TgAb
(present or absent), adjusted for age (‡45 vs. <45 years, and
‡ 55 vs. < 55 years) and sex.
Survival analysis was performed via log-rank tests and Cox
proportional hazards models for outcomes of disease-free
survival (DFS) and overall survival (OS). Serum TSH con-
centration was assessed both continuously and categorically.
Where event numbers were sufficient, age, sex, and ethnicity
were included in the models as potential confounders. The
proportional hazards assumption in Cox models was checked
by assessment for time interactions.
Results
Eligible subjects and comparison with full NTCTCS cohort
Of 3318 patients registered in the NTCTCS since 1996, serum
TSH was measured preoperatively in 617 patients, and TgAb
was measured perioperatively (preoperatively or within 3
months of surgery) in 1701 patients (Table 2). Both the TSH and
TgAb cohorts had a median follow-up time of 5.5 years. There
were slightly higher proportions of females and Caucasians
among the group with available TSH information (Table 2).
Those with TgAb information had a slightly higher prevalence
of previous radiation exposure (Table 2). Otherwise, there were
no differences between patients with available TSH/TgAb in-
formation and those without. Among 182 patients with avail-
able pre- and postoperative (within 3 months) TgAb status,
there was a 93% concordance of these results, with the 12 dis-
cordant positive results divided equally between pre- and
postoperative periods.
Serum TSH concentration
Cross-sectional analysis. The geometric mean for serum
TSH was higher in patients with high-risk versus low-risk
disease (1.48 mU/L vs. 1.02 mU/L; p = 0.006). When considered
Table 2. Comparison of Thyrotropin and Antithyroglobulin Antibodies Cohorts
with the Overall NTCTCS Population
Parameter
Overall differentiated





Number of patients (n) 3308 617 1701
Percent female (%) 72.2 76.3a 72.7
Age, years (mean – SD) 45.6 – 15.3 46.6 – 15.3 46.0 – 15.4
Histology (%)
Papillary 89.0 90.4 88.7
Follicular 6.8 7.6 7.8
Hürthle cell 4.2 2.0 3.5
Race/ethnicity (%)
Caucasian 83.6 74.8b 83.2
Asian 5.1 7.6 5.4
Hispanic 4.9 11.0 6.2
Black 4.4 5.3 4.4
Other 2.0 1.5 0.8
History of prior radiation exposure (%) 3.6 4.9c 4.3d
NTCTCS Stage (%)
I 44.1 45.7 42.7
II 27.8 24.4 28.2
III 24.0 25.2 25.3
IV 4.1 4.7 3.8
Outcomes (n)
Disease present at entry 385 82 211
Dated recurrence 298 37 169
Death 178 38 84
Disease-related death 58 13 30
Comparisons were made between those with TSH/TgAb values available, and those with missing data. The statistical differences were
found to be significant (ap = 0.01, bp = 0.01) or borderline significant (cp = 0.053) compared to patients with missing TSH values, and significant
(dp = 0.03) compared to patients with missing TgAb status.
TSH, thyrotropin; TgAb, antithyroglobulin antibodies.
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categorically, higher serum TSH concentration was associated
with high-risk disease (Fig. 1; ptrend = 0.03). The relationship
persisted in those aged ‡ 45 years after adjusting for sex (Table
3). Only 16 patients aged < 45 years were classified as having
high-risk disease. The difference in geometric mean for serum
TSH in this group was similar between high- and low-risk
patients to those aged ‡ 45 years, but this analysis did not reach
statistical significance, likely because of low numbers (Table 3).
The results did not change when using an alternate age cut
point of 55 years (not shown). Serum TSH level was also sig-
nificantly associated with the presence of gross extrathyroidal
extension ( p = 0.03) and cervical nodal metastases ( p = 0.003),
but neither tumor size ( p = 0.63) nor the presence of distant
metastases ( p = 0.31; Fig. 2).
Longitudinal outcomes analysis. Among those with TSH
information, 38 patients died from all causes. Among the 499
patients without residual disease at baseline, 37 patients had
timed recurrences recorded. Using categorical serum TSH and
assessing with the log-rank test, no relationship was seen with
DFS ( p = 0.93) or OS ( p = 0.48). Adjusted analyses could not be
performed due to low event numbers. Continuous serum TSH
analyses did not satisfy modeling assumptions and thus re-
sults are not reported.
Serum TgAb status
Cross-sectional analysis. On crude analysis, positive
TgAb was found in 17.8% of Stage III/IV patients versus
23.4% of Stage I/II patients (odds ratio = 0.71 [95% con-
fidence interval = 0.54–0.93]). However, when age and sex
were included in the models, the association was attenuated
and was no longer statistically significance (odds ratio = 0.85
[95% confidence interval = 0.60–1.20]). Altering the age cut
point did not alter the findings (not shown). TgAb status was
not significantly associated with serum TSH concentration
(geometric mean of 1.27 mU/L in TgAb positive patients vs.
1.00 mU/L in TgAb negative patients; n = 469; p = 0.20).
Longitudinal outcomes analysis. Among patients with
TgAb information, 84 died of all causes. Recurrence occurred
in 151 patients out of 1149 patients recorded as being free of
disease at baseline. TgAb status was not associated with DFS
or OS in either univariate or adjusted analyses (Table 4). Al-
tering the age cut point for the analysis again did not alter the
results (not shown).
Discussion
In this population of prospectively studied thyroid cancer
patients, we have found that a higher serum TSH concentra-
tion at diagnosis is associated with higher thyroid cancer
stage. Proportionally, patients with gross extrathyroidal ex-
tension and lymph node metastasis had higher serum TSH
concentrations. Assessment of long-term outcomes associated
with at-diagnosis serum TSH concentration is not possible
due to the low number of events at this follow-up.
Our analysis confirms and extends the majority of data
showing that higher serum TSH concentrations at the time of
diagnosis are associated with higher thyroid cancer stage
(3,18–22), versus a minority of studies that show no relation-
ship (23,24), utilizing the largest data set assessed thus far in
the literature. It is also in accord with clinical observations that
suppressing serum TSH in high-risk patients improves
prognosis (5–7). Extrathyroidal extension (20,21) and lymph
node metastases (19,21) have been reported to be associated
with serum TSH concentration in some studies, consistent
with our analysis. We found that higher serum TSH is asso-
ciated with gross extrathyroidal extension, indicating more
aggressive behavior. As in other studies (20,21), serum TSH
concentration and tumor size were not associated in our data.
This latter observation makes the possibility of reverse cau-
sation less likely, that is, that tumors with extrathyroidal ex-
tension replace so much normal thyroid tissue that they cause
an elevated serum TSH. The best cross-sectional evidence that
serum TSH is associated with tumors of high biologic ag-
gressiveness would be a finding that tumors with distant
metastasis have higher serum TSH. While our data are sug-
gestive of this (Fig. 2D), there are too few patients with meta-
static disease in the TSH cohort to demonstrate a statistically
significant association.
It is biologically plausible that higher TSH concentration
could lead to more aggressive DTC by influencing signaling
pathways implicated in adverse thyroid cancer prognosis.
Recent mouse model data suggest that TSH signaling pre-
disposes thyrocytes to Braf-induced transformation (25). In
humans, BRAF mutation-positive papillary thyroid cancers
are, in turn, associated with extrathyroidal extension, lymph-
FIG. 1. Proportion of patients with Stage III/IV differenti-
ated thyroid cancer according to serum thyrotropin (TSH)
category; ptrend = 0.03. Total n for this analysis is 615 because
two patients aged ‡ 45 with otherwise Stage I/II tumors had
missing tumor size data.
Table 3. Relationship of Thyroid Stage to Serum
Thyrotropin, Adjusting for Age and Sex
Stage
Geometric mean
serum TSH (mU/L) [CI] p
Age < 45 years
I/II (n = 275) 1.12 [0.90, 1.39]
0.29III (n = 16) 1.67 [0.79, 3.54]
Age ‡ 45 years
I/II (n = 156) 0.95 [0.71, 1.28]
0.01III/IV (n = 168) 1.52 [1.18, 1.95]
Under the NTCTCS staging system, patients <45 years of age with
distant metastases are classified as having Stage III disease.
CI, 95% confidence interval.
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node metastasis, and higher-stage disease (26–28). TSH re-
ceptor activation also influences other cellular pathways (29),
some of which are important in progressive follicular and
anaplastic carcinomas. A recent study demonstrating the
importance of Akt activation in tumor progression, invasion,
and distant metastasis used a mouse model (PV mice) which
features markedly elevated serum TSH levels (30). However,
it is unclear if less extreme elevations in serum TSH concen-
trations would significantly influence the Akt pathway to
produce more aggressive disease.
The implications of our study that higher serum TSH is
associated with worse thyroid cancer prognosis may have
clinical utility. Our findings suggest that those with elevated
TSH at diagnosis may benefit from heightened surveillance.
Furthermore, this information may enhance prognostic as-
sessment at initial diagnosis; and guide aggressiveness of
initial therapy as it relates to lymph node dissection. Current
risk stratification systems fail to explain a significant pro-
portion of the variation in risk of adverse outcomes (1,2), and
thus additional prognostic markers are needed. For these
potential applications to become reality, longitudinal out-
come data need to show not only that serum TSH concen-
tration is associated with thyroid cancer outcome, but also
that serum TSH provides incremental prognostic information
independent of current staging systems and established
prognostic factors. Future NTCTCS analyses may be able to
answer these questions.
Our analysis found no prognostic significance of baseline
TgAb status once the effects of age and sex were considered.
Whether or not autoimmune thyroiditis is associated with
thyroid cancer prognosis is controversial (9,10). Several
studies have reported improved prognosis associated with
FIG. 2. Relationship of prognostic markers of differentiated thyroid cancer (DTC) to serum TSH concentration. Prognostic
markers assessed were tumor size (A), neck nodal metastases (B), extrathyroidal extension (C), and distant metastases (D).
The center circles represent geometric means for serum TSH, and whiskers represent confidence intervals. *Statistically
significant differences between groups (Bonferroni-corrected for extrathyroidal extension).
Table 4. Survival Analysis for Antithyroglobulin Antibody Status
DFS OS
TgAb status Crude HR [CI] Adjusted HR [CI] Crude HR [CI] Adjusted HR [CI]
Negative 1 1 1 1
Positive 1.11 [0.76, 1.61] 1.12 [0.74, 1.69] 0.70 [0.40, 1.28] 0.98 [0.56, 1.72]
HR, hazard ratio; DFS, disease-free survival; OS, overall survival.
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either diffuse thyroiditis (31,32) or clinical/antibody markers
of autoimmunity (33), as distinguished from intratumoral
lymphocyte infiltration. However, only one of these studies
included a multivariate analysis (31). Other studies have not
confirmed a protective effect from autoimmune thyroid-
itis after accounting for potential confounders (34,35). Our
data suggest that perioperative TgAb status (as a marker
of thyroid autoimmunity) is not an independent predictor of
thyroid cancer stage or outcome. The univariate relationship
observed between TgAb status and thyroid cancer stage was
explained by the higher frequency of TgAb positivity in
younger females, who collectively had earlier-stage disease.
Our findings underscore the importance of assessing potential
confounders in the analysis of autoimmunity in the prognosis
of thyroid cancer.
Baseline TgAb status may be a nonspecific proxy of thyroid
autoimmunity, and this could limit the value of speculating
on the mechanistic implications of our results. Because TgAb
assessment occurred perioperatively, it could represent a
mixed population of patients with pre-existing autoimmunity
and those manifesting an immune response to tumor. Two
well-performed studies using multivariate analyses have
suggested that intratumoral lymphocytic infiltration is as-
sociated with better prognosis (36,37). It is possible that
pre-existing diffuse thyroid autoimmunity, as opposed to a
specific immune response to tumor cells, could have different
prognostic implications. Our data do not include information
about lymphocytic infiltration on histology or TPOAb status
because these variables were not included in registry data
collection, nor does it permit knowledge of whether patients
had pre-existing thyroid autoimmunity. However, the fact
that TgAb status was not associated with serum TSH con-
centration in our study suggests either that a significant
proportion of the TgAb positive patients did not have long-
standing autoimmune thyroiditis, or that many were well
treated with levothyroxine.
Several other potential limitations in our analysis need to
be considered. While the current registry datasets for base-
line TSH concentration and TgAb status are large compared
to the literature, the TSH data set in particular had few re-
currences and deaths (both all-cause and disease-specific
mortality). Three factors likely contributed to this: (i) the
small baseline sample size; (ii) the good prognosis of many
thyroid cancer patients; and (iii) the relatively short median
5.5 years of follow-up. Future registry analyses may over-
come these limitations. Data for serum TSH and TgAb status
were also absent in a substantial proportion of patients, al-
though those with available data appeared reasonably rep-
resentative of the wider NTCTCS cohort. Thus, while
selection bias is possible, there is no signal for this in the data.
It is also possible that unmeasured confounding may have
influenced our results. However, our analyses adjusted for
major potential confounders, and other than prior treatment
with levothyroxine, we are unaware of any obvious potential
confounders that should have been included in our models.
As discussed previously, interpretation of the TgAb data
should be limited to the setting of TgAb positivity, rather
than thyroid autoimmunity per se. Our data set also lacks
information on whether thyroid autonomy or Graves’ dis-
ease was the cause of patients’ preoperative subnormal TSH
levels. However, given that the proportion of high-risk pa-
tients increased through each higher serum TSH category,
this missing information is unlikely to alter our interpreta-
tion of the data.
In conclusion, this study adds weight to the hypothesis that
higher serum TSH concentration is associated with more ag-
gressive DTC. Definitive evidence for an association with
long-term outcome may be forthcoming with future registry
analyses. TgAb status was not an independent predictor of
thyroid cancer stage or outcome. Because it remains possible
that a specific immune response to tumor could be associated
with a better prognosis, future studies should assess prog-
nosis of thyroid cancers in patients with pre-existing auto-
immune thyroid disease.
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